1) Newly diagnosed epilepsy 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jen Langer interviews Prof. Martin Brodie about his paper on newly diagnosed epilepsy. Dr. Jennifer Fugate is reading our e-Pearl of the week about nocturnal wandering in adults. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about imaging modalities for diagnosis of mild cognitive impairment and Alzheimer disease. Over the next two weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. The participants had nothing to disclose except Prof. Brodie, Drs. Fugate, Burns and Morris.Prof. Brodie serves on the editorial boards of Seizure, Epilepsy & Behavior, CNS Drugs and Acta Neurologica Scandinavia; serves on scientific advisory boards for Pfizer Inc, UCB, Eisai Inc., GlaxoSmithKline, Novartis, Sanofi-aventis, Upsher-Smith Laboratories, Inc. and Lundbeck Inc; has received funding for travel from UCB; serves as a consultant for Eisai Inc.; serves on speakers' bureaus for UCB, GlaxoSmithKline, and Eisai Inc.; and has received research support from GlaxoSmithKline, and Eisai Inc.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.